Format

Send to

Choose Destination
Eur J Med Res. 2011 Apr 28;16(4):187-95.

Epidemiology and antifungal resistance in invasive candidiasis.

Author information

1
Institut f├╝r Medizinische Mikrobiologie, und Infektionsepidemiologie, Universit├Ątsklinikum Leipzig, Liebigstr, Germany. acr@medizin.uni-leipzig.de.

Abstract

The epidemiology of Candida infections has changed over the last two decades: The number of patients suffering from such infections has increased dramatically and the Candida species involved have become more numerous as Candida albicans is replaced as an infecting agent by various non-C. albicans species (NAC). At the same time, additional antifungal agents have become available. The different Candida species may vary in their susceptibility for these various antifungals. This draws more attention to in vitro susceptibility testing. Unfortunately, several different test methods exist that may deliver different results. Moreover, clinical breakpoints (CBP) that classify test results into susceptible, intermediate and resistant are controversial between CLSI and EUCAST. Therefore, clinicians should be aware that interpretations may vary with the test system being followed by the microbiological laboratory. Thus, knowledge of actual MIC values and pharmacokinetic properties of individual antifungal agents is important in delivering appropriate therapy to patients.

PMID:
21486733
PMCID:
PMC3352075
DOI:
10.1186/2047-783x-16-4-187
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center